1,598 results on '"Wang, Eunice S."'
Search Results
2. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia
3. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
4. A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia
5. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results
6. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
7. Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia
8. Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia
9. How I treat: secondary acute myeloid leukemia
10. Acute myeloid leukemia with LRRFIP1::FGFR1 rearrangement and a complex karyotype
11. KDM6B protects T-ALL cells from NOTCH1-induced oncogenic stress
12. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
13. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia
14. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial
15. An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML
16. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
17. A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
18. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy
19. Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes
20. Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML
21. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
22. Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy
23. Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
24. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
25. In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.
26. Impact of body mass index and karyotype on clinical outcomes in adolescents and young adults (AYA) with acute myeloid leukemia.
27. Covalent-103: A phase 1, open-label, dose-escalation and expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia (AL).
28. A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.
29. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
30. Acute Leukemia with KMT2A Rearrangement: A Master of Disguise
31. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
32. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
33. Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades
34. Outcomes of Adult Acute Myeloid Leukemia Treated With Gemtuzumab-Ozogamicin: Cue To Optimized Chemotherapy Backbone
35. Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia
36. A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia
37. Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
38. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
39. Germline variants drive myelodysplastic syndrome in young adults
40. Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis
41. A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit–positive Acute Myeloid Leukemia
42. PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias
43. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase
44. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
45. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801
46. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations
47. Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML
48. Clinical and functional significance of circular RNAs in cytogenetically normal AML
49. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
50. Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.